Table1 Baseline characteristics of the patients stratified by the primary endpoint
Variable | All subjects (n = 633) | MACE-free (n = 534) | MACE (n = 99) | P value |
|---|---|---|---|---|
Age, years | 68.02 ± 10.75 | 67.52 ± 10.91 | 70.72 ± 9.41 | 0.007 |
Female | 208 (32.8) | 176 (33.0) | 32 (32.3) | 0.902 |
BMI, kg/m2 | 24.90 ± 3.10 | 24.99 ± 3.14 | 24.35 ± 2.85 | 0.057 |
Smoking, n (%) | 284 (44.8) | 238 (44.6) | 46 (46.5) | 0.728 |
Previous PCI, n (%) | 68 (10.7) | 54 (10.1) | 14 (14.1) | 0.234 |
COPD, n (%) | 28 (4.4) | 21 (3.9) | 7 (7.1) | 0.163 |
Hypertension, n (%) | 477 (75.3) | 401 (75.1) | 76 (76.8) | 0.723 |
AF, n (%) | 52 (8.2) | 40 (7.5) | 12 (12.1) | 0.123 |
Previous Stroke, n (%) | 36 (5.6) | 33 (6.2) | 3 (3.0) | 0.314 |
SBP, mmHg | 133.66 ± 21.96 | 133.81 ± 21.66 | 132.86 ± 23.61 | 0.692 |
HR, bpm | 78.78 ± 14.89 | 78.24 ± 14.76 | 81.72 ± 15.30 | 0.033 |
cTnT, pg/ml | 30.41 (13.43, 484.75) | 28.09 (13.17, 457.30) | 56.68 (15.21, 608.90) | 0.077 |
BNP, pg/ml | 115.00 (42.10, 378.90) | 107.65 (40.00, 340.77) | 171.70 (50.30, 615.20) | 0.008 |
Scr (umol/L) | 77.90 (64.30, 97.55) | 77.10 (64.00, 95.70) | 82.40 (68.10, 116.60) | 0.016 |
FBG (mmol/L) | 8.38 ± 3.05 | 8.31 ± 3.03 | 8.78 ± 3.01 | 0.161 |
HbA1c | 7.60 ± 1.72 | 7.58 ± 1.77 | 7.60 ± 1.71 | 0.936 |
TG (mmol/L) | 1.56 ± 0.88 | 1.52 ± 0.83 | 1.77 ± 1.08 | 0.009 |
TC (mmol/L) | 4.39 ± 1.27 | 4.38 ± 1.25 | 4.45 ± 1.38 | 0.579 |
HDL (mmol/L) | 1.13 ± 0.29 | 2.65 ± 0.87 | 2.71 ± 0.99 | 0.472 |
LDL (mmol/L) | 2.66 ± 0.89 | 1.12 ± 0.29 | 1.14 ± 0.29 | 0.529 |
LVEF | 54.57 ± 9.71 | 55.16 ± 9.14 | 51.39 ± 11.89 |  < 0.001 |
AMI, n (%) | 284 (44.8) | 238 (44.6) | 46 (46.5) | 0.728 |
Diagnosis, n (%) | Â | Â | Â | 0.491 |
CCS | 90 (14.2) | 80 (15.0) | 10 (10.1) | Â |
UA | 259 (40.9) | 216 (40.4) | 43 (43.4) | Â |
NSTEMI | 144 (22.7) | 118 (22.1) | 26 (26.3) | Â |
STEMI | 140 (22.1) | 120 (22.5) | 20 (20.2) | Â |
Aspirin, n (%) | 613 (96.8) | 521 (97.6) | 92 (92.9) | 0.015 |
P2Y12 receptor inhibitor, n (%) | 626 (98.8) | 530 (99.3) | 96 (97.0) | 0.076 |
Statins, n (%) | 618 (97.6) | 523 (97.9) | 95 (96.0) | 0.234 |
β-blockers, n (%) | 452 (71.4) | 388 (72.7) | 64 (64.6) | 0.105 |
ACEI/ARB, n (%) | 320 (50.5) | 269 (50.4) | 51 (51.5) | 0.835 |
Diuretics, n (%) | 139 (21.9) | 106 (19.9) | 33 (33.3) | 0.003 |
Insulin, n (%) | 167 (26.3) | 133 (24.9) | 34 (34.3) | 0.05 |
Oral hypoglycemic agents, n (%) | 450 (71.0) | 388 (72.7) | 62 (62.6) | 0.043 |
MVD, n (%) | 473 (74.7) | 381 (71.3) | 92 (92.9) |  < 0.001 |
LM, n (%) | 45 (7.1) | 35 (6.6) | 10 (10.1) | 0.207 |
Calcified lesions, n (%) | 119 (48.7) | 92 (17.2) | 27 (27.3) | 0.019 |
Thrombosis, n (%) | 58 (9.1) | 48 (9.0) | 10 (10.1) | 0.725 |
Long lesion, n (%) | 396 (62.5) | 332 (62.2) | 64 (64.6) | 0.640 |
CTO, n (%) | 139 (21.9) | 101 (18.9) | 38 (38.4) |  < 0.001 |
Number of stents | 1.54 ± 0.94 | 1.53 ± 0.95 | 1.59 ± 0.88 | 0.582 |
Length of stents, mm | 40.82 ± 28.06 | 40.73 ± 28.30 | 41.29 ± 26.92 | 0.854 |
Tyg index | 9.08 ± 0.56 | 9.04 ± 0.56 | 9.26 ± 0.55 |  < 0.001 |
TyG index ≤ 9.04 | 315 (49.7) | 284 (53.2) | 31 (31.3) |  < 0.001 |
TyG index > 9.04 | 318 (50.2) | 250 (46.8) | 68 (68.7) |  < 0.001 |
bSS | 15.00 (9.00, 21.25) | 14.50 (8.00, 20.50) | 20.00 (14.00, 27.50) |  < 0.001 |
rSS | 4.00 (0.00, 9.00) | 3.00 (0.00, 8.00) | 8.00 (3.00, 13.00) |  < 0.001 |